Stock Analysis, Dividends, Split History

MDC / M.D.C. Holdings, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,801.47
Enterprise Value ($M)1,368.15
Book Value ($M)1,489.84
Book Value / Share26.40
Price / Book1.21
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 56,123,228
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 56,123,228
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.06
Return on Equity (ROE)0.11
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Real Estate Revenue Net0.00
Financial Services Revenue0.00
Home Building Revenue0.00
Net Income141.84
Earnings Per Share Basic2.54
Earnings Per Share Diluted2.48
Cash Flow Statement (mra) ($M)
Cash From Operations65.47
Cash from Investing57.79
Cash from Financing57.79
Identifiers and Descriptors
Central Index Key (CIK)773141
Related CUSIPS
552676958 055267610 552676908

Split History

Stock splits are used by M.D.C. Holdings, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Real Estate Sector Awaits Impact From Hurricane Florence

2018-09-15 seekingalpha
On a busy week of economic data and hurricane-related disruptions, US equities advanced 1% while real estate equities finished roughly flat. Housing-related categories await the impact of Hurricane Florence. (2-0)

REITs Resume Rally On Another Record Week For U.S. Markets

2018-09-01 seekingalpha
Another week, another record high for US equities. Encouraging progress on NAFTA trade talks highlighted an otherwise quiet week on the earnings and economic data front.

9 Housing Stocks to Buy

2018-08-31 investorplace
The U.S. economy looks like it’s getting stronger. Just this week, the GDP for last quarter was adjusted upward to 4.2% for the quarter. That almost doubled GDP in Q1. (2-1)

Homebuilders: Signs Of Softness

2018-08-27 seekingalpha
Homebuilding isn’t as easy as it used to be. After surging in 2017, homebuilders have slumped this year on concerns over a slowdown in the post-recession housing recovery. (5-0)

M.D.C. Holdings' (MDC) CEO Larry Mizel on Q2 2018 Results - Earnings Call Transcript

2018-08-01 seekingalpha
Good afternoon. We are ready to begin the M.D.C. Holdings Inc Second Quarter Earnings Conference Call. I will now turn it over to Kevin McCarty, Vice President of Finance and Corporate Controller. Sir, you may begin your call.

CUSIP: 552676108